Never Run Out Of Buyers To Sell To.

Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 30 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases.
Annual Revenue$250M to $500M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.